Transcription
Chris Eso 0:00
Chris Eso, Vice President of Business Development and Strategy for the cardiovascular portfolio. Goes back 13 years, I've been with Medtronic for that long. But I was in pharma and biotech prior to and kind of added to my experience with the medical device. And I started in coronary doing working on business development for drug eluting stents, the type of companies that we tend to meet with our early stage companies, and we're following them and have been tracking them for multiple years. Usually, you know, we're we're watching them watching their progress, and at some point, we will then look at making an investment and or an acquisition when we meet with venture capitalists, right, it's really trying to understand how they're looking at their portfolio, a cardiovascular perspective. So do they have, you know, some of our key areas that we look at cardiovascular ablation, renal denervation, Structural Heart, those are some of the bigger areas that we're looking for. So it's a range of early stage, technology companies that either are on our radar that we've been tracking for a while, or new companies that we haven't learned from, and we're attending the sessions and hearing the short pitches, as well as having meetings with them. Additionally, we're having meetings with venture capitalists and understanding what's in their portfolio. LSI is putting on a really good event. I went to the Dana Point one and, you know, really focused on the US based companies and so coming to to Europe and Barcelona, for this LSI event, really to have a concentration on the European companies that maybe we don't get to see that often.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
